Home › Breast Cancer › NCT06085833
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions (ANGEL)
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients aged ≥ 18 years * Ability to understand and the willingness to sign a written informed consent. * Indication for breast biopsy for diagnostic purposes * ECOG performance status of 0 to 3. Exclusion Criteria: * Conditions that, in the investigator's opinion, might indicate that the subject is not suitable for the study.
About the study
This prospective, blinded, single-arm study aims to test the performance of nanomechanical phenotype in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response compared to the gold standard of histopathological assessment. The study involves patients with suspicious breast lesions who will undergo a breast biopsy procedure indicated by standard of care. The nanomechanical phenotype will be measured on the freshly obtained breast biopsies or tissue from breast surgeries.
What is being tested
- Nanomechanical Phenotype Test (diagnostic test)
Sponsor: ARTIDIS AG · Participants: 2,706 · Started: Nov 2, 2023
Contact the study team
- Julia Ortega, DMSc, MHS, PA · Phone: 2404980176
- Marko Loparic, MD,PhD · Phone: +41 61 633 29 95
Official record on ClinicalTrials.gov — NCT06085833
Locations in the U.S.
| Texas | University of Texas Southwestern Medical Center, Dallas Baylor College of Medicine, Houston MD Anderson Cancer Clinic - Mays Clinic, Houston |
| Washington | University of Washington, Seattle |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.